(Reuters) – Pfizer‘s (NYSE:PFE) chief executive said on Tuesday he would prefer to wait for clarity on U.S. tax reform before engaging in any big deals in order to get a better understanding of any potential acquisition target’s value. The largest U.S. drugmaker has been under increasing pressure from investors and Wall Street to pull off […]
MassDevice Earnings Roundup
Mazor Robotics shares dip despite Q2 beat
Shares in Mazor Robotics (NSDQ:MZOR) fell today despite the robotic surgical platform developer posting 2nd quarter earnings that handily topped expectations on Wall Street. The Caesarea, Israel-based company posted losses of $3.7 million, or 8¢ per share, on sales of $15.5 million for the 3 months ended June 30, seeing losses shrink 9.6% while sales grew […]
AcelRx’s pain relief drug-device combo succeeds in late-stage trial
AcelRx Pharmaceuticals (NSDQ:ACRX) touted device functionality outcomes today from the Phase III trial of its Zalviso drug-device combination product. Zalviso is designed to deliver a sublingual formulation of an opioid, sufentanil, to adult patients with moderate-to-severe pain in a hospital setting using a hand-held, pre-programmed system. The device allows patients to self-administer sufentanil as often as […]
Align Technology shares dip despite Q2 beat
Shares in Align Technology (NSDQ:ALGN) fell today despite the orthodontic device maker beating expectations on Wall Street with its 2nd quarter earnings results. The San Jose, Calif.-based company posted profits of $69.2 million, or 85¢ per share, on sales of $356.5 million for the 3 months ended June 30, for bottom-line growth of 37.9% while sales […]
C.R. Bard faces DoJ FCA probe, posts Q2 earnings
C.R. Bard (NYSE:BCR) said today that the US Department of Justice is investigating possible False Claims Act violations related to the sales and marketing of its FloChec and QuantaFlow devices, alongside releasing Q2 earnings which topped expectations on The Street. The Murray Hill, N.J.-based company said this month it was served with a “civil investigative demand” […]
Omnicell shares surge after Q2 beat
Shares in Omnicell (NSDQ:OMCL) soared today after the company beat expectations on Wall Street with its second quarter results. The Mountain View, Calif.-based company posted profits of $837,000, or 2¢ per share, on sales of $180.9 million for the 3 months ended June 30, for sales growth of 4.6% compared with the same period last year. Get […]
Cyber attack stalls manufacturing for Merck, narrows outlook
Merck (NYSE:MRK) narrowed its full-year earnings outlook while announcing its second quarter results today. The company revealed that an international cyber attack, which hit the drugmaker in June, halted some of its manufacturing operations. While touting its second quarter financial results, Merck said that it doesn’t yet fully comprehend the magnitude of the disruption caused by the […]
NuVasive shares drop amid mixed Q2 earnings, reorganization efforts
Shares in NuVasive Inc. (NSDQ:NUVA) fell today after the medical device maker posted 2nd quarter earnings that beat earnings per share expectations but fell short on sales with shrinking profits compared to the previous year, alongside announcing a number of changes to its executive roster. The San Diego, Calif.-based company posted profits of $12.7 million, or […]
AtriCure gains on Q2 revenue beat, raised outlook
AtriCure (NSDQ:ATRC) shares gained today after the medical device company yesterday reported higher-than-expected sales and raised its outlook for the rest of the year. The Mason, Ohio-based cardiovascular device company posted losses of -$6.9 million, or -21¢ per share, on sales of $45.2 million for the three months ended June 30, paring its losses by -16.1% […]
Tandem shares slide after Q2 sales miss
Shares in Tandem Diabetes Care (NSDQ:TNDM) fell yesterday after the medical device maker missed sales expectations but beat EPS estimates on Wall Street with its second quarter results. The San Diego, Calif.-based company posted a loss of -$21.8 million, or -44¢ per share, on sales of $21.3 million for the 3 months ended June 30, for bottom-line […]
Hill-Rom slips on fiscal Q3 sales miss, lowered outlook
Hill-Rom (NYSE:HRC) shares came under pressure in pre-market trading today after the medical device giant posted fiscal third-quarter results that missed the consensus sales forecast and lowered its outlook for the rest of the year. Chicago-based Hill-Rom reported profits of $6.0 million, or 9¢ per share, on sales of $689.1 million for the three months ended […]